| HIR | DLR | P value | |
|---|---|---|---|
| Dose-length product (DLP) [mGy∙cm] | 176.1±37.1 | 106.4±50.0 | <0.001 |
| Volume CT dose index (CTDIvol) [mGy] | 11.5±2.2 | 6.9±3.2 | <0.001 |
| Effective dose [mSv] | 2.5±0.5 | 1.5±0.7 | <0.001 |
Figure 1. Organ-specific dose value comparison between DLR and SBIR. The use of DLR provides the potential for a 52% reduction in volume CT dose index and a mean of 53% in organ-specific reductions. Figure adapted from reference (Brady et al. 2021).
Figure 1. Dual-phase CT performed on a 7-year-old patient with suspected pancreatic trauma. Left: Coronal image from an arterial phase acquisition of the abdomen reconstructed with AiCE (0.3 mSv). Right: Coronal image from a portal venous phase acquisition of the abdomen and pelvis reconstructed with AiCE (0.5 mSv).
The information on this website is not intended for consumers. It is directed exclusively for healthcare professionals and persons who are engaging in purchasing or the business of wholesaling therapeutic goods (in accordance with the Therapeutic Goods Advertising Code Instrument 2021).
By selecting “Continue” you are indicating that you are the intended audience. Click “Cancel” to be redirected to the Canon Medical Systems global website.
© Canon Medical Systems ANZ Pty Limited.
© Canon Medical Systems ANZ Pty Limited.